Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to loss of $10.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -42.79%. A quarter ago, it was expected that this company would post a loss of $4 per share when it actually produced earnings of $0.75, delivering a surprise of 118.75%.Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39617 Aligos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-4724808 (State or other ju ...

EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2024. "This quarter we reached a key milestone when we announce ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2024. “This quarter we reached a key milestone when we announced the positive topline HERALD data in MASH subjects,” stated Lawrence Blatt, Ph.D., MBA, Chairman, Presiden ...

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately. “We are pleased to welcome David to the Aligos team during this exciting time for the company,” said Lesley Ann Calhoun, Executive Vice President and Ch ...

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will participate at two investor conferences being webcast in October: H.C. Wainwright 8th Annual MASH Virtual Conference Fireside Chat at 3:00pm ET/12:00pm PT on October 7, 2024 H.C. Wainwright 5th Annual Viral Hepatiti ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aligos Therapeutics, Inc. (ALGS) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Aligos Therapeutics, Inc. is a member of our Medical group, which includes 1019 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector R ...

Aligos Therapeutics, Inc. (ALGS) closed the last trading session at $14.48, gaining 5.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $108.33 indicates a 648.1% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $57.74. While the lowest estimate of $75 indicates a 418% increase from the current price level, the most optimisti ...

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will effect a 1-for-25 reverse stock split of its shares of common stock. The reverse stock split will become effective at 12:01 am ET on Monday, August 19, 2024. The Company’s common stock is expected begin trading on ...

Aligos Therapeutics, Inc. (ALGS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individ ...